“Second Patient Dies in Zafgen Obesity Drug Trial”

Two patients have now died while taking the drug beloranib in an obesity drug trial. Both patients were in the active arm of the study and had received the drug rather than a placebo. Zafgen did not say whether it believed the drug had caused the blood clotting in the lungs that led to the patient’s death.

Article →

***

Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.

LEAVE A REPLY